Mirati Therapeutics (MRTX) Misses Q4 EPS by 14c

Mirati Therapeutics (NASDAQ: MRTX) reported Q4 EPS of ($3.51), $0.14 worse than the analyst estimate of ($3.37). Revenue for the quarter came in at $930 thousand versus the consensus estimate of $2.44 million.

For earnings history and earnings-related data on Mirati Therapeutics (MRTX) click here.

You May Also Be Interested In

• SYNNEX Corp. (SNX) Tops Q3 EPS by $1.04, Beats on Revenue; Offers Q4 Guidance
• NeoVolta Inc. (NEOV) Misses Q3 EPS by 17c
• Cintas beats estimates but stock edges lower